What Dextran 40 Treats: Main Uses and Benefits

The therapeutic use of Dextran 40 is applicable within clinical settings that involve acute or unstable symptom patterns. The medication is generally applied in settings marked by temporary physiological imbalance across three main clinical domains.

Dextran 40 is commonly used to help manage the symptoms related to circulatory instability that arise from severe fluid loss, such as in hemorrhage, extensive burns, and trauma. Its main therapeutic benefit supports the restoration of circulating blood volume, which may assist with the stabilization of blood pressure and may assist with the maintenance of blood supply to vital organs during acute episodes. It is also relevant for easing the symptomatic risk of blood clots (thromboembolism) in surgical patients, and for addressing impaired microcirculation where symptoms related to systemic imbalance are noticeable.

“The supportive intent is to assist with easing the overall symptom load when symptoms related to systemic imbalance are acutely challenging.”

This medicine is considered relevant in situations where symptoms linked to organ-specific functional stress are present and during specialized procedures like cardiopulmonary bypass. This supportive relief helps maintain a sense of stability when symptoms are more noticeable, assisting with the overall symptom load.

---

Quick Fact: Addresses Acute Circulatory Instability

---

Regulatory References

1. NIH StatPearls overview of Dextran therapy

Who Can and Cannot Use Dextran 40?

Official regulatory documentation strictly defines which populations are eligible to use Dextran 40. The medicine must not be used (is contraindicated) in patients with a known hypersensitivity to dextran.

Absolute prohibitions apply to populations with severe organ dysfunction or blood disorders:

• Marked Cardiac Decompensation (severe heart failure).
• Renal Disease with Severe Oliguria or Anuria (little or no urine output).
• Marked Hemostatic Defects, including low platelet counts (thrombocytopenia) or other coagulation disorders.

Restricted and Conditional Use

Use is subject to specific regulatory limitations for other groups:

• Age: Safety and effectiveness have not been established in neonates. For older adults, doses require careful selection and monitoring due to potential declines in renal or cardiac function.
• Pregnancy/Lactation: The medicine should be administered to a pregnant woman only if clearly needed. Caution is advised for mothers who are nursing.
• Fluid Status: Use requires caution in patients at risk of circulatory fluid overload, such as those with pulmonary edema, and in individuals with impaired renal clearance.

Interactions with other medicines and products

The official regulatory profile for Dextran 40 interactions is defined by pharmacodynamic reinforcement and specific administration constraints, rather than metabolic or transporter-mediated effects.

Pharmacodynamic Interactions and Restrictions

The combination of Dextran 40 with certain medicinal products is classified as contraindicated due to an increased risk of hemorrhage. This restriction specifically applies to substances that cause marked hemostatic defects, such as the anticoagulants heparin and warfarin. Official prescribing information notes that co-administration with other anticoagulants (e.g., desirudin) and antiplatelet agents (e.g., Abciximab) may lead to a reinforcing pharmacodynamic effect, increasing the overall potential for bleeding.

Interaction Type	Interacting Substances	Outcome / Restriction
Contraindicated	Heparin, Warfarin, etc.	Prohibited combination due to increased bleeding risk.
Pharmacodynamic	Anticoagulants, Antiplatelet agents	Increased hemorrhagic potential is documented.

Administration and Pharmacokinetic Profile

A mandatory procedural constraint requires that additive medications should not be delivered through the plasma volume expander solution. This rule is in place to avoid physical incompatibility or inaccurate dosage.

Regarding drug metabolism, authoritative government sources state that there are no documented pharmacokinetic interactions with Dextran 40 involving CYP enzymes or drug transporters. Furthermore, caution is advised when Dextran 40 formulations containing sodium are administered alongside medications that promote fluid retention, such as corticosteroids or carbenoxolone, due to the potential for compounded effects on fluid and sodium balance.

Colloid Osmotic Action and Intravascular Volume Expansion

Dextran 40's primary function is to modulate intravascular volume by acting as a colloid osmotic agent. Its large molecular structure restricts it primarily to the bloodstream, exerting an osmotic pressure that facilitates the shift of free water from the interstitial space across the capillary membrane into the vascular compartment. This physicochemical interaction consequently raises plasma volume and influences the dynamics of central circulatory parameters.

---

Modulation of Blood Rheology and Clearance

Simultaneously, the molecule engages mechanisms that influence blood rheology by modifying the surface interactions of red blood cells and platelets. This action reduces cellular cohesion and inhibits aggregate formation, influencing blood viscosity and flow dynamics in the microcirculation. Regarding clearance, Dextran 40 is gradually broken down by the enzyme dextranase into smaller fragments; the remaining portion is filtered by the kidneys. This slow, enzyme-mediated suppression of the molecule leads to a sustained osmotic action within targeted pathways.

Dextran 40 is administered exclusively via intravenous (I.V.) infusion as a 10% solution prepared in either 0.9% Sodium Chloride or 5% Dextrose. The precise usage protocol involves strictly regulated dose maximums and adherence to required preparation steps.

Administration Scope

Dosing Context	Regimen Principle	Duration Limit
Acute Volume Expansion	Initial rapid infusion of 10 mL/kg (or 500 to 1,000 mL). The total maximum dose is 20 mL/kg in the first 24 hours, followed by 10 mL/kg per day thereafter.	Therapy is generally limited to a maximum of five days.
Prophylaxis Regimen	500 mL is administered daily for two to three days post-operation, followed by an intermittent schedule of 500 mL every second or third day.	Treatment may continue for up to two weeks while the clinical risk persists.

Required Procedural Steps

Administration requires mandatory pre-treatment steps and specialized equipment. Dextran 1 must be administered prior to the Dextran 40 infusion as part of the established administration protocol. The infusion solution is intended for a single dose only, and the administration set must include a filter. For special populations, pediatric dosing is based on weight, while the initiation of therapy for older adults may use doses at the lower end of the established dose range. This usage protocol dictates a controlled, time-limited course of therapy.

Research Evidence / Overview of Studies for Dextran 40

---

Evidence for Use in Acute Circulatory Instability and Volume Loss

Dextran 40 was evaluated in studies of acute circulatory crises characterized by severe fluid or blood loss, such as trauma, burns, or hemorrhage. The evidence includes Randomized Controlled Trials (RCTs) and observational studies primarily from the initial period of its clinical evaluation. This section will summarize the structure of this evaluation.

These studies focused on short-term changes, specifically monitoring physiological strain or stress outcomes. Researchers examined measures related to blood pressure indices, urine output, and the immediate restoration of circulating blood volume in adult patients experiencing acute loss.

Findings describe patterns observed in the studies that related to achieving the measured volume expansion in the bloodstream. These research results were described in the initial studies of Dextran 40. However, because many of these studies are historical, they provide limited context when reviewing modern research on fluid therapy. Long-term effects are not fully established beyond the acute resuscitation phase.

---

Evidence for Preventing Blood Clotting in Surgical Patients

Dextran 40 was evaluated in trials related to thromboembolic complications (blood clots) in patients undergoing certain surgical procedures. The evidence for this use is drawn from controlled clinical trials and subsequent systematic reviews and meta-analyses that pooled data from multiple surgical settings. This section will describe the body of research that examined these conditions.

In these studies, researchers monitored outcomes related to clot formation, such as the recorded incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE). Research also examined biological factors related to blood flow in the smallest vessels, known as microcirculation.

Studies report how symptoms evolved in the observed populations related to blood flow and coagulation markers. Trials described variations in the recorded rates of DVT and PE across different types of surgical patients. However, findings were mixed across different surgical contexts. Evidence quality varies across studies, and the available data provide limited insight into findings that were heterogeneous across the full range of surgical contexts evaluated.

---

Research in Specialized and Complex Clinical Contexts

Studies focused on specific complications, such as Acute Kidney Injury (AKI) in patients with decompensated liver cirrhosis, or cerebral vasospasm (CVS) following subarachnoid hemorrhage (SAH). These research scenarios typically involve temporary physiological imbalance. Researchers examined outcomes like the changes in AKI markers based on laboratory values, or the status of cerebral blood flow in the studied populations.

Data are still emerging in these areas. The observed findings describe patterns measured in very small sample sizes. Research involving concurrent use of other agents complicates the interpretation of Dextran 40's singular contribution in these settings. This kind of research contributes to the broader evidence landscape but does not provide widely applicable findings.

---

Long-Term Study Duration and Follow-up

The majority of research on Dextran 40 has focused on short-term symptom changes and immediate physiological outcomes related to the acute crisis. Studies generally tracked patients for a duration of only hours to days. Even in the studies involving surgical clot prevention, the primary follow-up durations were limited to the immediate post-operative period. Consequently, long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of the initial response or any consequences that may manifest months or years after treatment.

---

Evidence in Special Patient Groups

The principal clinical trials and historical research primarily included adult populations. Data for certain groups remain insufficient. Specifically, there is limited information available from high-quality studies on the use of Dextran 40 in children or in older adults who may have additional comorbid conditions. Furthermore, research examining temporary physiological imbalance in vulnerable groups is scarce. Results apply only to the populations studied, meaning the applicability of findings to these special patient groups is not well-characterized by official research.

---

Research Gaps and What Remains Uncertain

A key gap is that comparative evidence is lacking against many modern fluid therapy options that have since been developed. The established evidence base is categorized as moderate to low, primarily due to the modest sample sizes found in many of the studies exploring specific uses. In summary, evidence highlights what is known — and what is still uncertain. The available research contributes to the evidence landscape regarding historical fluid therapy and its evaluation in preventing certain surgical complications. However, certainty remains low for many specialized applications, and more up-to-date, large-scale studies are still needed to provide comprehensive data in complex patient settings.

Key Studies & References

1. Low Molecular Weight Dextran Therapy: StatPearls [Internet] (Used for overview of main uses and benefits)
2. Dextran Injection: MedlinePlus Drug Information (Used for dual action and general properties)

Common questions about Dextran 40 (FAQ)

Q: Is Dextran 40 the same thing as a blood thinner?

Dextran 40 is officially classified as a plasma volume expander, meaning its main purpose is to increase the amount of fluid circulating in the bloodstream. However, official sources also note that Dextran 40 influences the function of platelets and red blood cells. Because of this, it is described as having properties that influence the blood's ability to clot.

Q: How quickly does Dextran 40 start to work after it is given?

Dextran 40 is administered through an intravenous infusion, and its intended effect of increasing blood volume is considered rapid. Official product information describes its action as producing significant and quick increases in circulating blood volume and blood pressure.

Q: How long does the effect of Dextran 40 last in the body?

The effects of Dextran 40 are sustained within the body. Approximately 70% of the dose is removed from the body and excreted in the urine within the first 24 hours of the infusion. The remaining portion of the molecules stays in the bloodstream for several days, contributing to a prolonged osmotic action.

Q: Is Dextran 40 safe for people with diabetes?

Official product information notes that Dextran 40 solutions sometimes contain dextrose, which is a form of sugar. Therefore, regulatory documents indicate that caution is advised when administering these dextrose-containing formulations to patients who have known diabetes mellitus.

Q: Is it normal to feel dizzy or lightheaded after receiving Dextran 40?

Dizziness and lightheadedness are not explicitly listed as common side effects of Dextran 40 in regulatory documents. However, the official product information notes hypotension, or low blood pressure, as a possible adverse reaction.

Q: What are the signs of a serious problem after getting Dextran 40?

The most serious adverse reaction officially listed is a severe allergic (anaphylactoid) reaction. Signs associated with this serious reaction are reported to include the development of a generalized rash or hives, wheezing, nausea, vomiting, or a significant drop in blood pressure.

Q: Can Dextran 40 affect the results of certain blood tests?

Yes, the presence of Dextran 40 in the blood may interfere with the results of certain laboratory tests. This interference is noted for tests measuring blood sugar, bilirubin, and total protein levels. Official regulatory protocols indicate that blood samples for typing and cross-matching are typically drawn before the Dextran 40 infusion begins.

Q: How is Dextran 40 different from Dextran 70?

Both are types of plasma expanders, but the difference lies in the average size of the molecules, known as the molecular weight. Dextran 40 has an average molecular weight of 40,000 Daltons, while Dextran 70 is larger, at 70,000 Daltons. This size difference influences how long the solution remains in the bloodstream and its specific actions on circulation.

Q: What should be monitored while a patient is receiving Dextran 40?

Regulatory documents describe that clinical staff monitor for signs of circulatory overload, especially in patients with heart conditions, and for signs of possible renal failure (kidney problems) or bleeding complications due to the medicine's effect on coagulation.

Q: What is the difference between a crystalloid and a colloid like Dextran 40?

Colloids, like Dextran 40, contain large molecules that mostly stay contained within the blood vessels to effectively expand blood volume. Crystalloids, such as saline solution, contain small molecules like salts and sugars that move freely out of the vessels and into the surrounding tissues to replace overall body fluid.

Q: Can Dextran 40 be used alongside blood transfusions?

Official documents describe Dextran 40's use as a temporary volume replacement, often when whole blood or blood products are not immediately available. Due to its potential to interfere with blood testing, regulatory protocols typically state that blood samples for cross-matching are drawn prior to the Dextran 40 infusion.

Q: Is the use of Dextran 40 restricted to hospital settings?

Regulatory documents indicate that the administration of Dextran 40 is a complex procedure. It must be given by intravenous infusion using specialized equipment and requires close clinical monitoring of the patient's condition. These requirements generally limit its use to an acute care or specialized clinical environment.

How to Store and Dispose of Dextran 40?

Dextran 40 injection must be stored according to strict temperature requirements to maintain product stability and sterility, as mandated by regulatory labeling.

Official Storage Conditions

Requirement	Specifics
Temperature	Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F).
Constraint	The product must be protected from freezing.
Stability Check	Do not use if crystallization has occurred or if the solution is cloudy.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Dextran 40 is supplied in a single-dose container, and any unused portion remaining after administration must be discarded. Expired or unused medicine must be disposed of properly according to local governmental guidelines, and generally should not be discarded in household trash or poured down a drain.